Data builds on Roche's dominance in primary progressive MS

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

Fenebrutinib Shows Promise to Reduce Disability Progression in Primary Progressive Multiple Sclerosis

Phase 3 data show oral fenebrutinib slows primary progressive multiple sclerosis disability progression versus ocrelizumab, with early upper-limb gains and a manageable safety profile.

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial

Roche on Saturday detailed just how much its BTK inhibitor was deemed non-inferior compared to its blockbuster medicine Ocrevus in a late-stage trial in primary progressive multiple sclerosis. Fenebrutinib cut the risk of disability progression ...

Genentech reports fenebrutinib Phase III results for PPMS

Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, for treating PPMS.The post Genentech reports fenebrutinib Phase III results for PPMS appeared first on Hospital Management.